Tumor Immunology and Immunotherapy

Program Leaders

Scott Abrams, PhD
Pawel Kalinski, MD, PhD

Contact Person

Cheryl Krieger
Department Administrator
Tel: 716 845-3256
Fax: 716 846-1322

The Tumor Immunology and Immunotherapy Program (TII) seeks to understand the interaction between the immune system and malignancies, and translate this knowledge into the development of novel diagnostic, preventive, and treatment regimens. The Program, which takes advantage of close interactions between laboratory and clinical scientists, relies on the validation in animal model systems of results derived from in vitro investigations in the laboratory. The information derived from in vitro and in vivo studies is then utilized to develop novel strategies to address clinical questions. In turn, the questions generated from investigations in the clinical setting are brought back to the laboratory and to animal model systems. This bi-directional exchange of information between laboratory investigators and clinical investigators provides the opportunity to apply basic science to investigate molecular mechanisms underlying clinically relevant questions.

The Tumor Immunology and Immunotherapy Program is structured into three distinct but interrelated themes:

1) Mechanisms of immunological tumor rejection
2) Microenvironment and host-tumor interactions
3) Immunotherapy

Theme 1: “Mechanisms of immunological tumor rejection” aims to characterize the molecular mechanisms for processing and presentation of antigens, and the structural basis of defects in histocompatibility antigens expression by malignant cells. Furthermore, this theme investigates the impact of changes in the expression and function of histocompatibility antigens on interactions between malignant cells and the host’s immune system as well as on the outcome of immunotherapy of malignant diseases.

It has become clear that tumor cell-autonomous changes, such as loss of histocompatibility antigens, represents only some of the mechanisms by which tumors escape control by endogenous or therapeutically elicited immune responses.

Theme 2: “Microenvironment and host-tumor interactions” seeks to define and understand the role of the interactions between the tumor cells and the surrounding microenvironment on tumor cell survival as well as modulating the host anti-tumor immune responses. This research also broadly includes the inflammatory milieu within which carcinogenesis occurs, as well as how the immune system itself can be a supportive component of the tumor microenvironment.

Theme 3: “Immunotherapy” utilizes the information derived from the other two themes in order to develop and characterize molecular and immunologic strategies for manipulating the innate and adaptive immune responses to malignancy. It is expected that the developed strategies will improve our ability to select, monitor and treat patients with immunotherapy.

These themes are dynamic and interactive, continually evolving to translate programmatic data for clinical application.

Program Members

 Scott Abrams, PhD
 Sophia Balderman, MD
 Joseph Barbi, PhD
 Matthew Barth, MD
 Gurkamal Chatta, MD
 Thinle Chodon, MD, PhD
 Oscar Colegio, MD, PhD
 Michael J. Ciesielski, PhD
 Oscar Colegio, MD, PhD
 Marc Ernstoff, MD
 Sharon S. Evans, PhD
 Robert Fenstermaker, MD
 Carmelo Gaudioso, MD, PhD
 Francisco J. Hernandez-Ilizaliturri, MD
 Fumito Ito, MD, PhD
 Pawel Kalinski, MD, PhD
 Keith Kirkwood, DDS, PhD 
 Richard Koya, MD, PhD
 Danuta Kozbor, PhD
 Joseph Lau, PhD
 Kelvin Lee, MD
 Junko Matsuzaki, PhD
 Philip McCarthy, MD
 Austin Miller, PhD
 Hans Minderman, PhD
 Kirsten Moysich, PhD
 Jason Muhitch, PhD
 Michael J. Nemeth, PhD
 Kunle Odunsi, MD, PhD
 Scott Olejniczak, PhD
 Thomas Schwaab, MD, PhD
 Brahm Segal, MD
 Ben K. Seon, PhD
 Joseph J. Skitzki, MD
 Yasmin Thanavala, PhD
 Takemasa Tsuji, PhD
 Paul Wallace, PhD
 Eunice Wang, MD
 Emese Zsiros, MD, PhD